Jaguar Health will present at Lytham Partners Fall 2022 Investor Conference on September 28 and at Ladenburg Thalmann 2022 Healthcare Conference on September 29


Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.


Jaguar CEO Lisa Conte will also participate in an orphan drug panel presentation on September 28 at the Lytham Partners Fall 2022 investor conference

SAN FRANCISCO, CA/ACCESSWIRE/September 22, 2022/ Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that on September 28, 2022, Lisa Conte, President, Founder and CEO of Jaguar, will present at the virtual conference Lytham Partners Fall 2022 Investor Conference in addition to participating in a panel presentation titled “Orphan Drugs: Innovative Companies Addressing Rare Diseases” at the conference. Additionally, Conte will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022.

“I was so happy to be invited to speak to the orphan drug panel at the Lytham Partners conference,” Conte said. “Jaguar believes that clinical advancements related to our target orphan indications of short bowel syndrome (SBS) and congenital diarrheal disease (CDD) could be transformational in terms of creating value and recognition for society over the next six orphan drugs accounted for 52% of the total 50 new drugs approved by the FDA’s Center for Drug Evaluation and Research in 2021,1 and, according to a report by Research and Markets, the global orphan drug market is expected to reach $229.71 billion in 2026.2 The search for potential rare disease indications for the novel mechanism of action of our crofelemer-based drug has become a strategic focus for Jaguar and Napo Therapeutics, the Jaguar rare disease company established in 2021. Jaguar is the majority shareholder of this company based in Italy. company, and Napo Therapeutics holds an exclusive license for crofelemer in Europe. Our focus on rare diseases complements the expected completion in the first half of 2023 of enrollment in our OnTarget pivotal trial for cancer treatment-related diarrhea (CTD). We believe this Phase 3 trial for our planned follow-up indication for crofelemer will also bring transformative value to Jaguar. »

Company presentations:

  • Lytham Partners Fall 2022 Virtual Investor Conference: Jaguar’s webcast presentation will be available for viewing at 9:00 a.m. EST on Wednesday, September 28, 2022 by clicking here. The webcast will also be archived and available for replay.
  • Orphan Drug Panel Presentation at Lytham Partners Fall 2022 Investor Conference: Jaguar management also plans to participate in a panel at the conference titled “Orphan Drugs: Innovative Companies Addressing Rare Diseases.” The panel, which will also be held virtually, will be held on Wednesday, September 28, 2022 at 2:00 p.m. EST. To access the panel, click here.
  • Ladenburg Thalmann 2022 Healthcare Conference: Jaguar’s presentation will take place on Thursday, September 29, 2022 from 10:00 a.m. to 10:25 a.m. in Track 2 of the St. Germain III room at the Sofitel Hotel New York in New York City. To watch the live webcast of Jaguar’s presentation, click here. The webcast will also be archived and available for replay.

About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics and Jaguar Animal Health

Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing novel herbal, non-opioid, and sustainably-derived prescription medicines for people and animals with gastrointestinal disorders, including chronic and debilitating diarrhea. Jaguar Health’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc., is focused on the development and commercialization of proprietary human plant-based pharmaceutical products from plants responsibly harvested from rainforest areas. Our product candidate, crofelemer, is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for the prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics SpA (f/k/a Napo EU SpA), an Italian company established by Jaguar Health in Milan, Italy, in 2021, which focuses on expanding access to crofelemers in Europe. Jaguar Animal Health is a trading name of Jaguar Health.

For more information about Jaguar Health, visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com.

Forward-looking statements

Certain statements contained in this press release constitute “forward-looking statements”. These include statements regarding Jaguar’s expectations that on September 28, 2022, the company’s management will present at the Lytham Partners Fall 2022 investor conference and participate in a presentation by the orphan drug group at the event. , Jaguar’s expectation that company management will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, the Company’s belief that clinical advancements related to the target orphan indications of SBS and CDD could be transformational in terms of value creation and recognition for the Company over the next approximately six months, the third-party projection that the global orphan drug market could reach $229.71 billion in 2026, the Company expects that its focus on rare diseases will complete the planned H1 2023 completion of OnTarget trial enrollment of the Company, and the Company’s belief that the OnTarget Phase 3 trial brings transformative value to Jaguar. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “expect”, “plan”, “aim”, “anticipate”, ” could”, “intend”, “target”, “project”, “consider”, “believe”, “estimate”, “predict”, “potential”, or “continue” or the negative form of these terms or other similar expressions. The forward-looking statements contained in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections regarding future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not intend to update or to publicly review forward-looking statements co contained herein, whether as a result of new information, future events, changed circumstances or otherwise.

1https://globalgenes.org/2022/01/12/a-group-of-innovative-orphan-drugs-win-fda-approval-in-2021/

2 https://www.researchandmarkets.com/reports/5553689/orphan-drugs-global-market-report-2022-by

Contact:
Pierre Hodge
Jaguar Health, Inc.
[email protected]
Jaguar – JAGX

THE SOURCE: Jaguar Health, Inc.

See the source version on accesswire.com:
https://www.accesswire.com/716998/Jaguar-Health-to-Present-at-Lytham-Partners-Fall-2022-Investor-Conference-on-September-28th-and-at-Ladenburg-Thalmann-2022- Health-Conference-on-September-29

Valerie J. Wallis